IPP Bureau
PM Modi hails pharma industry for its innovation
By IPP Bureau - November 19, 2021
Betting big on talent, resources, and the ecosystem required for innovation and enterprise, Prime Minister Narendra Modi invited stakeholders to ideate in India, innovate in India and Make in India for the world
Novavax and Serum Institute receive EUA for Covovax
By IPP Bureau - November 18, 2021
The vaccine will be manufactured and marketed in the Philippines by SII under the brand name Covovax
Illumina and Sequoia Capital China selects startups for Genomics
By IPP Bureau - November 18, 2021
First-of-its-kind Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics
Zydus Cadila receives U.S.FDA approval for leukaemia injection
By IPP Bureau - November 18, 2021
Nelarabine is in a class of medications called antimetabolites
Daiichi Sankyo initiates Phase 2 trial of mRNA Covid-19 vaccine in Japan
By IPP Bureau - November 18, 2021
It is anticipated to be safe and efficacious by targeting the receptor-binding domain (RBD) of the new coronavirus
Roche launches cobas 5800, a new molecular diagnostics system
By IPP Bureau - November 18, 2021
The system is a compact new addition to the Roche Molecular portfolio, providing efficiency, simplicity and timely results to laboratories of all sizes.
US govt signs deal with GSK and Vir Biotechnology to buy sotrovimab, a Covid-19 treatment
By IPP Bureau - November 18, 2021
The final data from the trial showed sotrovimab reduces hospitalisation and risk of death by 79% in adults with mild-to-moderate Covid-19 who are at high risk of progression to severe disease
AstraZeneca’s Covid-19 drug offers 83% protection over six months
By IPP Bureau - November 18, 2021
Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic Covid-19, with no severe disease or deaths
Sluggish exports to cap pharma revenue growth at 9% this fiscal
By IPP Bureau - November 17, 2021
A CRISIL study of 207 pharmaceutical companies that account for 55% of the Rs 3.2 lakh crore-a-year sector revenue indicates as much.
Private equity firm Carlyle partners with Viyash Life Sciences for pharma platform
By IPP Bureau - November 17, 2021
Viyash has ten manufacturing facilities in India with a combined capacity of 2000 KL as well as one formulation facility in the US, and is now one of India’s leading mid-tier integrated API and formulation players
Pfizer seeks EUA from U.S. FDA for Covid-19 drug
By IPP Bureau - November 17, 2021
If approved or authorized, Paxlovid would be the first oral antiviral of its kind, to combat SARS-CoV-2
Biocon Biologics and Viatris announce US launch of Semglee
By IPP Bureau - November 17, 2021
Branded and unbranded versions of the first-ever interchangeable biosimilar in the U.S. provide more affordable options for the millions of Americans living with diabetes
PM to inaugurate first Global Innovation Summit of Pharmaceuticals sector
By IPP Bureau - November 17, 2021
The Summit will also witness participation of Union Minister of Health & Family Welfare and Chemicals & Fertilizers Dr. Mansukh Mandaviya
Cipla launches Spirofy for early diagnosis of COPD
By IPP Bureau - November 17, 2021
It is India’s first pneumotach based portable wireless Spirometer for diagnosis of Chronic Obstructive Pulmonary Disorder (COPD)
World’s first Donepezil patch to treat Alzheimer approved in South Korea
By IPP Bureau - November 17, 2021
Launching in 2022, its availability will be expanded to the global market
